Author:
Laborde Nicole D., ,Pleasants Elizabeth,Reddy Krishnaveni,Atujuna Millicent,Nakyanzi Teopista,Chitukuta Miria,Naidoo Sarita,Palanee-Phillips Thesla,Baeten Jared M.,Montgomery Elizabeth T.
Funder
National Institute of Allergy and Infectious Diseases
Publisher
Springer Science and Business Media LLC
Subject
Infectious Diseases,Public Health, Environmental and Occupational Health,Social Psychology
Reference39 articles.
1. Baeten JM, Palanee-Phillips T, Brown ER, et al. Use of a vaginal ring containing dapivirine for HIV-1 prevention in women. N Engl J Med. 2016;375:2121–32.
2. Montgomery ET, van der Straten A, Chitukuta M, et al. “It’s inside my body and it’s mine”: Acceptability and use of a dapivirine vaginal ring in a phase III trial. AIDS. 2017;31:1159–67.
3. Nel A, Bekker LG, Bukusi E, et al. Safety, acceptability and adherence of dapivirine vaginal ring in a microbicide clinical trial conducted in multiple countries in Sub-Saharan Africa. PLoS ONE. 2016;11(3):e0147743.
4. Kiser P, Johnson T, Clark J. State of the art in intravaginal ring technology for topical prophylaxis of HIV infection. AIDS Rev. 2012;14(1):62–77.
5. Malcolm RK, Edwards K-L, Kiser P, Romano J, Smith TJ. Advances in microbicide vaginal rings. Antiviral Res. 2010;88:S30–9.